间变性淋巴瘤激酶重排非小细胞肺癌的CT特征:系统综述与Meta分析
该系统综述与Meta分析检索PubMed和Embase至2019年2月20日,纳入16项研究共3113例非小细胞肺癌患者,比较伴与不伴ALK重排者的CT特征。伴ALK重排者更常见实性、中央型、≤3 cm的病灶,增强CT衰减值更低,N2或N3病变、癌性淋巴管炎、胸腔积液、胸膜转移更常见,肺转移较少见;异质性I²=0-80%,未见显著发表偏倚(p=0.15)。
要点
- 伴ALK重排的非小细胞肺癌更常见实性(OR=2.86)、中央型(OR=2.72)及≤3 cm(OR=0.57)病灶。
- 伴ALK重排者N2或N3病变(OR=5.63)、癌性淋巴管炎(OR=3.46)、胸腔积液(OR=1.91)、胸膜转移(OR=1.81)更常见。
- 伴ALK重排者增强CT衰减值更低(MD=-4.79 HU),肺转移较少见(OR=0.66)。
核心结论
- 伴ALK重排的非小细胞肺癌与不伴ALK重排者相比具有若干独特的CT特征,这些CT生物标志物可能有助于识别可能伴ALK重排的患者。
研究设计与样本
- 系统综述与Meta分析,检索PubMed和Embase数据库至2019年2月20日,纳入评估伴与不伴ALK重排的非小细胞肺癌CT特征的研究。
- 共纳入16项研究、3113例非小细胞肺癌患者,采用诊断准确性研究质量评价工具第2版(QUADAS-2)评估方法学质量。
- 采用随机效应模型以比值比(OR)或均数差(MD)合并CT特征与ALK重排的关联,用不一致性指数(I²)检验异质性,用漏斗图和Egger检验评估发表偏倚。
关键影像表现/征象
- 伴ALK重排者较不伴者更常见实性病灶(OR=2.86)。
- 伴ALK重排者较不伴者更常见中央型位置(OR=2.72)。
- 伴ALK重排者病灶≤3 cm更常见(OR=0.57)。
- 伴ALK重排者增强CT衰减值更低(MD=-4.79 HU)。
- 伴ALK重排者N2或N3病变(OR=5.63)、癌性淋巴管炎(OR=3.46)、胸腔积液(OR=1.91)、胸膜转移(OR=1.81)更常见,肺转移较少见(OR=0.66)。
诊断标准与关键数值
- 伴ALK重排患者总体患病率为17%(528/3113)。
- CT特征与ALK重排关联的异质性范围为I²=0-80%。
- 发表偏倚检验未见显著发表偏倚(p=0.15)。
局限性
- CT特征间存在异质性,I²范围为0-80%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. The purpose of this study was to perform a systematic review and meta-analysis regarding CT features of non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) rearrangement. MATERIALS AND METHODS. The PubMed and Embase databases were searched up to February 20, 2019. Studies that evaluated CT features of NSCLC with and without ALK rearrangement was included. Methodologic quality was assessed using Quality Assessment of Diagnostic Accuracy Studies-2. The association between CT features and ALK rearrangement was pooled in the form of the odds ratio (OR) or the mean difference (MD) using the random-effects model. Heterogeneity was examined using the inconsistency index (I2). Publication bias was examined using funnel plots and Egger tests. RESULTS. Sixteen studies were included, consisting of 3113 patients with NSCLC. The overall prevalence of patients with ALK rearrangement was 17% (528/3113). Compared with NSCLC without ALK rearrangement, on CT images those with ALK rearrangement were more frequently solid (OR = 2.86), central in location (OR = 2.72), and 3 cm or smaller (OR = 0.57); had lower contrast-enhanced CT attenuation (MD = -4.79 HU); more frequently had N2 or N3 disease (OR = 5.63), lymphangitic carcinomatosis (OR = 3.46), pleural effusion (OR = 1.91), or pleural metastasis (OR = 1.81); and less frequently had lung metastasis (OR = 0.66). Heterogeneity varied among CT features (I2 = 0-80%). No significant publication bias was seen (p = 0.15). CONCLUSION. NSCLC with ALK rearrangement had several distinctive CT features compared with that without ALK rearrangement. These CT biomarkers may help identify patients likely to have ALK rearrangement.
引用
- Kim TH, Woo S, Yoon SH, et al. CT Characteristics of Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangement: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2019. PMID: 31414902. doi:10.2214/AJR.19.21485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。